STAT+: Liquid biopsy study suggests a better way to decide which colorectal cancer patients need chemo

They’re far too small to be seen by even the most sophisticated medical imaging device. But bits of tumor DNA adrift in a patient’s blood are an important bellwether for whether cancer will return — and, as a new study shows, can predict which treatments are likely to work.

Scientists reported in the journal Nature Medicine on Monday that colorectal cancer patients who had tumor DNA in their blood after surgery were far more likely to have their cancer return. But the key finding was that it was the patients with this circulating tumor DNA who needed and benefited from chemotherapy, regardless of their cancer stage or other risk factors, while those without this DNA didn’t benefit from chemo.

Continue to STAT+ to read the full story…